The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target
- 25 March 2019
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 15 (6) , 629-637
Abstract
Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibodies production and immune complex deposition with systemic clinical manifestations. Interleukin (IL)-17-producing cells play a crucial role in disease pathogenesis and represent an attractive therapeutic target. Areas covered: This review provides an update on the possibility of targeting IL-17 in SLE. The rational for this approach as well as currently available and future targets are discussed. Expert opinion: Although human expression studies and animal models indicate that IL-17 blocking may be a promising therapeutic strategy for SLE, direct evidence for IL-17 inhibition in SLE patients is unavailable. Biologic therapies and small-molecule drugs that target IL-17 production are required for the achievement of a favorable clinical effect in SLE patients.Keywords
Funding Information
- Leading Initiative for Excellent Young Researchers of the Ministry of Education, Culture, Sports, Science and Technology (16810055)
This publication has 125 references indexed in Scilit:
- cAMP response element modulator α controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupusProceedings of the National Academy of Sciences, 2012
- Induction of PP2A Bβ, a regulator of IL-2 deprivation-induced T-cell apoptosis, is deficient in systemic lupus erythematosusProceedings of the National Academy of Sciences, 2011
- Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5Nature Immunology, 2011
- The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and MetabolismImmunity, 2010
- Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activityArthritis & Rheumatism, 2010
- Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupusProceedings of the National Academy of Sciences, 2009
- Ca2+/Calmodulin-dependent Protein KinasesCellular and Molecular Life Sciences, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- The Biological Functions of T Helper 17 Cell Effector Cytokines in InflammationImmunity, 2008
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003